Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.

By Yixin Wang, J. Klijn, Yi Zhang, Anieta M. Sieuwerts, M. Look, Fei Yang, D. Talantov, M. Timmermans, M. M. Meijer-van Gelder, Jack Yu and 4 more. The Lancet, 2005

2,816 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/73d6948a5fb62bd8c3fbbd612b1064003bcb2222

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Genetics

In Pathology and Forensic Medicine

Citations in the corpus

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors (2011, background): “Recently, several molecular tests for prediction of breast cancer prognosis have been developed in order to aid clinical decision making (3-5).”
Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. (2008, background): “June 1, 2008 ( 30 ) revealed that 25% of the TCM-exposed hMSC markers are up-regulated in the basals, 15% are up-regulated in luminals, and <5% are up-regulated in the HER2+ subtype of human breast”
Genome-wide analysis of estrogen receptor binding sites (2006, neutral): “dtd" [ ]> Recent work has focused on identifying gene expression signatures in breast cancer subtypes that predict response to specific treatment regimes and improved disease outcom”
Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling (2011, methodology): “Many of these signatures have also been shown to be prognostic factors and identify patients at increased risk of developing distant metastases [45, 46], including a 70gene prognosis signature [1, 44], a 76 gene prognosis signature [47] and a 21-gene classifier for paraffin-embedded tissues (Oncotyp”
L1 Penalized Estimation in the Cox Proportional Hazards Model (2009, positive): “We used four large and well-known gene expression data sets with a survival response: Van de Vijver (Van de Vijver et al., 2002, 295 80 J. J. Goeman: L1 penalized estimation r 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.biometrical-journal.com subjects, 79 events and 4919 covariates), Rosenw”
Statistical strategies for avoiding false discoveries in metabolomics and related experiments (2007, result): “A comparison of two studies using hundreds of samples found respectively 76 (Wang et al., 2005) and 70 (van 't Veer et al., 2002; van de Vijver et al., 2002) 'significant' genes, but only 3 of them were in fact the same (Ein-Dor et al., 2006 )!”
Identification of diagnostic subnetwork markers for cancer in human protein-protein interaction network (2010, methodology): “We obtained two independent breast cancer datasets from the large-scale expression studies in Wang et al. [10] (referred as the USA dataset) and van ’ t Veer et al. [9] (referred as the Netherlands dataset).”
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas (2007, methodology): “have identified a 16-gene signature associated with distant metastasis in ER-negative breast carcinomas [14].”
Latent bone metastasis in breast cancer tied to Src-dependent survival signals (2009, background): “Approximately twothirds of these cases were lymph node negative at diagnosis, and were not subject to adjuvant therapy after primary tumor resection (Wang et al., 2005; Yu et al., 2007).”
GOBO: Gene Expression-Based Outcome for Breast Cancer Online (2011, neutral): “A multitude of microarray-based gene signatures have been derived stratifying breast cancer into subtypes [1,2,24], identifying patients at risk [5,6,8,9,11,12], and predicting response to therapeutic agents [3,4].”
Research review: Polygenic methods and their application to psychiatric traits. (2014, background): “The genomics era has allowed good progress in subtyping of cancers (e.g. ER +ve/ER – ve and over-expression of HER2 as a breast-cancer subtype (Wang et al., 2005; Slamon et al., 1987) or K-ras mutations in colorectal cancer and EGFR mutations in lung cancer, reviewed in (Ferraldeschi & Newman,…”